[{"id":"ef70bd40-bf79-48c4-9e4c-bf5799b604fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04605731","created_at":"2021-01-19T20:31:23.461Z","updated_at":"2025-02-25T16:45:12.247Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer","source_id_and_acronym":"NCT04605731","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2025-02-06"},{"id":"dcbd3293-1182-4c12-8316-c5f16bc55d47","acronym":"STRATUM","url":"https://clinicaltrials.gov/study/NCT05377034","created_at":"2023-01-30T19:59:50.852Z","updated_at":"2024-07-02T16:35:13.314Z","phase":"Phase 2","brief_title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","source_id_and_acronym":"NCT05377034 - STRATUM","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 04/26/2025","primary_completion_date":" 04/26/2025","study_txt":" Completion: 10/26/2026","study_completion_date":" 10/26/2026","last_update_posted":"2024-03-22"},{"id":"98d02899-95e2-4460-970e-d8cfe1ea3235","acronym":"","url":"https://clinicaltrials.gov/study/NCT05315687","created_at":"2022-04-07T13:56:31.508Z","updated_at":"2024-07-02T16:35:22.912Z","phase":"Phase 2","brief_title":"Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy","source_id_and_acronym":"NCT05315687","lead_sponsor":"Emory University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-19"},{"id":"26d46d69-11f8-4786-88dd-d7c97f75f519","acronym":"","url":"https://clinicaltrials.gov/study/NCT02195011","created_at":"2021-01-18T10:15:51.950Z","updated_at":"2024-07-02T16:35:27.168Z","phase":"Phase 2","brief_title":"Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases","source_id_and_acronym":"NCT02195011","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/04/2017","primary_completion_date":" 06/04/2017","study_txt":" Completion: 06/04/2017","study_completion_date":" 06/04/2017","last_update_posted":"2023-12-05"},{"id":"bf705715-1d46-4cbb-8ef1-bdaf34b86246","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512692","created_at":"2021-01-29T07:10:33.982Z","updated_at":"2024-07-02T16:36:20.470Z","phase":"","brief_title":"90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT02512692","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 05/25/2021","primary_completion_date":" 05/25/2021","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2021-11-19"},{"id":"08521900-d74e-42bd-847f-88dedfb2155d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02913417","created_at":"2021-01-18T14:18:14.326Z","updated_at":"2024-07-02T16:36:31.566Z","phase":"Phase 1/2","brief_title":"Yttrium90, Ipilimumab, \u0026 Nivolumab for Uveal Melanoma With Liver Metastases","source_id_and_acronym":"NCT02913417","lead_sponsor":"David Minor, MD","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/10/2016","start_date":" 10/10/2016","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-04-19"}]